brain malignant astrocytoma. Malignant neoplasm of brain
Conditions
Interventions
Intervention 1: Intervention group 1 (12-cycle): After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters bod
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Newly diagnosed glioblastoma and anaplastic astrocytoma age between 18 and 70 years Karnofsky Performance Scale Index equal or more than 60 percent signed informed consent
Exclusion criteria
Exclusion criteria: chronic hepatic, renal or cardiac failure history of hematologic malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival. Timepoint: One year after the treatment is completed. Method of measurement: Patient follow-up.;Progression-free survival. Timepoint: 12 months after the treatment is completed. Method of measurement: brain imaging and physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anemia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Neutropenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Thrombocytopenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Alopecia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: physical examination.;Nausea. Timepoint: Before each session of monthly chemotherapy. Method of measurement: history taking.;Vomiting. Timepoint: Before each session of monthly chemotherapy. Method of measurement: history taking. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohammadreza Saghafi
Mashhad University of Medical Sciences
Outcome results
None listed